Skip to main content
. 2021 Feb 11;3(3):173–184. doi: 10.1002/acr2.11232

Figure 3.

Figure 3

Hazard ratios (HRs) (unadjusted and adjusted) for tofacitinib initiators versus biological disease‐modifying antirheumatic drug (bDMARD) initiators in the propensity score–trimmed population. Tofacitinib initiators primarily received tofacitinib 5 mg twice daily. HZ, herpes zoster; MACE, major cardiovascular adverse events; NMSC, nonmelanoma skin cancer; SIEs, serious infection events.